MOTS-c levels in teen PCOS look similar
In a small 2026 study of teens, blood levels of the peptide MOTS-c looked broadly similar in polycystic ovary syndrome and controls, and a tested mitochondrial variant was not seen in this group.
MOTS‑c is a small peptide encoded by mitochondrial DNA that has been discussed as a potential metabolic signal, including in conversations about insulin sensitivity. That makes it tempting to ask a simple question in a condition like polycystic ovary syndrome (PCOS), where insulin resistance and metabolic risk often matter.
Is MOTS‑c noticeably different in people with PCOS?
A 2026 observational study in adolescents suggests the answer is, at least in this cohort, “not by much.” The underlying study is Are serum MOTS‑c levels and MOTS‑c m.1382A>C polymorphism related to polycystic ovary syndrome? (2026).
How the teen cohort was tested
The researchers recruited adolescents aged 12 to 18 diagnosed with PCOS, plus a control group with regular menstruation. They measured MOTS‑c in blood (serum) and also checked for a specific mitochondrial genetic variant called m.1382A>C, which has been linked in other contexts to metabolic traits.
This is not a trial and it is not a test of whether MOTS‑c “treats” anything. It is a basic association study: do levels differ between groups, and do they track with other clinical measures.
What changed, and what didn’t
On average, MOTS‑c levels were numerically higher in the PCOS group than in controls, but the difference did not reach conventional statistical significance. Within the PCOS group, MOTS‑c levels also did not show clear relationships with the measured anthropometric or metabolic parameters.
For the genetic piece, everyone in this sample carried the same (wild-type) genotype at m.1382A>C, meaning this particular variant could not explain anything in this cohort.
Why a near-null result still matters
Negative or near-null results are useful in peptide research because they correct a common mental shortcut: if a peptide is involved in “metabolic biology,” it should show up cleanly in every metabolic-adjacent condition.
In real biology, signals can be subtle, context-dependent, tissue-specific, or downstream rather than causal. A blood measurement may also miss what is happening locally in tissues.
So the most responsible takeaway from this paper is modest. In this adolescent cohort, serum MOTS‑c did not separate PCOS from controls in a dramatic way, and the specific mitochondrial variant they tested was not present.
What would clarify the picture next
This study does not tell us whether MOTS‑c behaves differently in adult PCOS, in different populations, or in subgroups defined by the severity of insulin resistance. It also does not answer whether tissue-level MOTS‑c biology matters more than serum levels.
If MOTS‑c ends up being relevant to PCOS biology at all, the next step would look like careful replication in larger cohorts, with clearer phenotyping and, ideally, a way to link the peptide signal to a mechanism rather than just a correlation.